Transmission of HIV-1 Drug Resistance

  • Laura Marije Hofstra
  • Jean-Claude Schmit
  • Annemarie M. J. Wensing
Living reference work entry

Abstract

Infection with an HIV strain harboring drug resistance-related mutations is referred to as transmitted drug resistance (TDR) or primary resistance. As transmitted drug resistance increases the risk of virological failure, current guidelines recommend to perform drug resistance testing at baseline in all newly diagnosed individuals to guide the choice of antiretroviral therapy.

The prevalence of TDR varies among regions, risk groups, and drug classes due to different exposure to antiretroviral therapy (ART), risk behavior, and access to therapy. Of concern in developed countries is the rising prevalence of mutations associated with NNRTI resistance, a drug class frequently used in first-line therapy which has a low genetic barrier for development of resistance. In resource-limited settings (RLS), rollout of ART with limited virological monitoring frequently results in the risk of prolonged virological failure with selection and accumulation of drug resistance mutations and subsequent transmission of drug resistance. Most surveys in RLS showed still low to moderate prevalence of TDR, but greater coverage of ART is associated with a higher prevalence of TDR. Also in RLS the rise in prevalence of TDR is mostly driven by NNRTI resistance, which is of particular concern as this drug class constitutes the foundation of current first-line ART regimens and prophylaxis for prevention of mother-to-child transmission.

Keywords

Europe Codon Nucleoside Malaysia Nigeria 

References

  1. Barth RE et al (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10(3):155–166CrossRefPubMedGoogle Scholar
  2. Barth RE et al (2012) Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 17(2):377–386CrossRefPubMedGoogle Scholar
  3. Bennett DE et al (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4(3):e4724PubMedCentralCrossRefPubMedGoogle Scholar
  4. Blick G et al (2007) The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 195(9):1250–1259CrossRefPubMedGoogle Scholar
  5. Boden D et al (1999) HIV-1 drug resistance in newly infected individuals. JAMA 282(12):1135–1141CrossRefPubMedGoogle Scholar
  6. Boyd SD et al (2011) Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther 16(2):257–261PubMedCentralCrossRefPubMedGoogle Scholar
  7. Brenner BG et al (2007) High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 195(7):951–959CrossRefPubMedGoogle Scholar
  8. Brenner BG et al (2008) Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 22(18):2509–2515PubMedCentralCrossRefPubMedGoogle Scholar
  9. Brenner BG et al (2012) Spread of sub-epidemics resistant to non-nucleoside analogues among treatment-naive MSM: Montreal. In: 19th conference on retroviruses and opportunistic infections, Seattle, p Paper # 73Google Scholar
  10. Burchell AN et al (2012) Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002–09. J Antimicrob Chemother 67(11):2755–2765CrossRefPubMedGoogle Scholar
  11. Castor D et al (2012) Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr 61(1):1–8PubMedCentralCrossRefPubMedGoogle Scholar
  12. Castro H et al (2013) Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 208:1459–1463PubMedCentralCrossRefPubMedGoogle Scholar
  13. Collins JA et al (2004) Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 78(2):603–611PubMedCentralCrossRefPubMedGoogle Scholar
  14. Cong ME et al (2011) Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques. Virology 412(2):435–440CrossRefPubMedGoogle Scholar
  15. Cossarini F et al (2011) Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. J Acquir Immune Defic Syndr 56(2):e51–e54CrossRefPubMedGoogle Scholar
  16. de Ronde A et al (1996) First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. AIDS 10(2):231–232CrossRefPubMedGoogle Scholar
  17. Eigen M (1993) Viral quasispecies. Sci Am 269(1):42–49CrossRefPubMedGoogle Scholar
  18. Erice A et al (1993) Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 328(16):1163–1165CrossRefPubMedGoogle Scholar
  19. Frentz D et al (2011) Transmission of HIV resistant to non-nucleoside RT inhibitors is rising in MSM in Europe. In: 13th European AIDS conference, Belgrade, p Abstract PS1/5Google Scholar
  20. Geretti AM, Armenia D, Ceccherini-Silberstein F (2012) Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 25(6):677–686CrossRefPubMedGoogle Scholar
  21. Gianella S, Richman DD (2010) Minority variants of drug-resistant HIV. J Infect Dis 202(5):657–666PubMedCentralCrossRefPubMedGoogle Scholar
  22. Goodman DD et al (2011) Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25(3):325–333CrossRefPubMedGoogle Scholar
  23. Grant RM et al (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2):181–188CrossRefPubMedGoogle Scholar
  24. Gupta RK et al (2012) Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380(9849):1250–1258PubMedCentralCrossRefPubMedGoogle Scholar
  25. Halvas EK et al (2010) Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis 201(5):672–680PubMedCentralPubMedGoogle Scholar
  26. Hamers RL et al (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11(10):750–759CrossRefPubMedGoogle Scholar
  27. Hamers RL et al (2013) Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 8(1):19–26CrossRefPubMedGoogle Scholar
  28. Harrison L et al (2010) The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 24(12):1917–1922CrossRefPubMedGoogle Scholar
  29. Hecht FM et al (1998) Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339(5):307–311CrossRefPubMedGoogle Scholar
  30. Hirsch MS et al (1998) Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society – USA Panel. JAMA 279(24):1984–1991CrossRefPubMedGoogle Scholar
  31. Hirsch MS et al (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37(1):113–128CrossRefPubMedGoogle Scholar
  32. Hirsch MS et al (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47(2):266–285CrossRefPubMedGoogle Scholar
  33. Hofstra LM et al (2013a) Stable proportion but increasing number of HIV-1 diagnoses with transmitted drug resistance across Europe. In: 14th European AIDS conference, BrusselsGoogle Scholar
  34. Hofstra LM et al (2013b) Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients. J Antimicrob Chemother 68(6):1246–1250CrossRefPubMedGoogle Scholar
  35. Hue S et al (2009) Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 83(6):2645–2654PubMedCentralCrossRefPubMedGoogle Scholar
  36. Huigen M, Albert J, Lindstrom A (2006) Compensatory fixation explains long term persistence of the M41L in HIV-1 reverse transcriptase in a large transmission cluster. In: 15th international HIV drug resistance workshop: basic principles and clinical implications, SitgesGoogle Scholar
  37. Jain V et al (2010) Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002–2009. PLoS One 5(12):e15510PubMedCentralCrossRefPubMedGoogle Scholar
  38. Jain V et al (2011) Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203(8):1174–1181PubMedCentralCrossRefPubMedGoogle Scholar
  39. Johnson JA et al (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5(7):e158PubMedCentralCrossRefPubMedGoogle Scholar
  40. Katzenstein DA, Holodniy M (1995) HIV viral load quantification, HIV resistance, and antiretroviral therapy. AIDS Clin Rev 96:277–303Google Scholar
  41. Kiertiburanakul S et al (2013) Comparisons of primary HIV-1 drug resistance between recent and Chronic HIV-1 infection within a sub-regional cohort of Asian patients. PLoS One 8(6):e62057PubMedCentralCrossRefPubMedGoogle Scholar
  42. Kim D et al (2013) Trend in transmitted HIV-1 ARV drug resistance-associated mutations: 10 HIV surveillance areas, US, 2007–2010. In: 20th conference on retroviruses and opportunistic infections, Atlanta, Paper #149Google Scholar
  43. Kuritzkes DR et al (2008) Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 197(6):867–870CrossRefPubMedGoogle Scholar
  44. Larder BA et al (1993) Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365(6447):671–673CrossRefPubMedGoogle Scholar
  45. Leigh Brown AJ et al (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187(4):683–686CrossRefPubMedGoogle Scholar
  46. Li JZ et al (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305(13):1327–1335PubMedCentralCrossRefPubMedGoogle Scholar
  47. Li JZ et al (2013) Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 207(6):893–897PubMedCentralCrossRefPubMedGoogle Scholar
  48. Little SJ et al (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347(6):385–394CrossRefPubMedGoogle Scholar
  49. Little SJ et al (2008) Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82(11):5510–5518PubMedCentralCrossRefPubMedGoogle Scholar
  50. Lorenzi P et al (1999) Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 13(2):F17–F21CrossRefPubMedGoogle Scholar
  51. Markowitz M et al (2005) Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 365(9464):1031–1038CrossRefPubMedGoogle Scholar
  52. Mayers DL et al (1995) Prevalence and clinical course of persons seroconverting with AZT-resistant HIV-1 in Switzerland, Australia and the United States between 1988 and 1994. AIDS Res Hum Retroviruses 11(suppl 1):S162 (abstract)Google Scholar
  53. Metzner KJ et al (2005) Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19(16):1819–1825CrossRefPubMedGoogle Scholar
  54. Oette M et al (2006) Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41(5):573–581CrossRefPubMedGoogle Scholar
  55. Paredes R et al (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201(5):662–671PubMedCentralPubMedGoogle Scholar
  56. Perelson AS et al (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255):1582–1586CrossRefPubMedGoogle Scholar
  57. Peuchant O et al (2007) Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther 12(4):559–562PubMedGoogle Scholar
  58. Pillay D et al (2006) The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 20(1):21–28CrossRefPubMedGoogle Scholar
  59. Pingen M et al (2011) Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 66(7):1467–1480CrossRefPubMedGoogle Scholar
  60. Pingen M et al (2014) Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model. Retrovirology 11(1):113Google Scholar
  61. Quinn TC et al (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342(13):921–929CrossRefPubMedGoogle Scholar
  62. Sawe F et al (2013) Superiority of routine viral load monitoring in rural Kenya: the Kericho Clinic-based ART Diagnostic Evaluation (CLADE) Trial. In: 20th conference on retroviruses and opportunistic infections, AtlantaGoogle Scholar
  63. Schoffelen AF et al (2013) Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa. PLoS One 8(3):e58526PubMedCentralCrossRefPubMedGoogle Scholar
  64. Schuurman R et al (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171(6):1411–1419CrossRefPubMedGoogle Scholar
  65. Siripassorn K et al (2010) Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting. AIDS Res Hum Retroviruses 26(2):139–148CrossRefPubMedGoogle Scholar
  66. Stadeli KM, Richman DD (2013) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 18(1):115–123PubMedCentralCrossRefPubMedGoogle Scholar
  67. Swartz JE et al (2015) Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. J Antimicrob Chemother pii:dkv033 [Epub ahead of print]Google Scholar
  68. Toni TA et al (2009) Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 53(4):1670–1672PubMedCentralCrossRefPubMedGoogle Scholar
  69. Trotter AB et al (2013) Systematic review of HIV drug resistance in Southeast Asia. AIDS Rev 15(3):162–170PubMedCentralPubMedGoogle Scholar
  70. Vandamme AM et al (2004) Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 9(6):829–848PubMedGoogle Scholar
  71. Vercauteren J et al (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200(10):1503–1508CrossRefPubMedGoogle Scholar
  72. Violin M et al (2004) Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18(2):227–235CrossRefPubMedGoogle Scholar
  73. Wainberg MA et al (2011) Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother 66(10):2346–2349CrossRefPubMedGoogle Scholar
  74. Wawer MJ et al (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191(9):1403–1409CrossRefPubMedGoogle Scholar
  75. Wensing AM, Boucher CA (2003) Worldwide transmission of drug-resistant HIV. AIDS Rev 5(3):140–155PubMedGoogle Scholar
  76. Wensing AM et al (2005a) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192(6):958–966CrossRefPubMedGoogle Scholar
  77. Wensing AM et al (2005b) Comparative disease progression observed in newly diagnosed patients infected with drug resistant and susceptible HIV-1, the FORECAST-study: no signs for increased virulence. In 3rd IAS conference, Rio de JaneiroGoogle Scholar
  78. Wensing AM et al (2014) 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 22(3):642–50Google Scholar
  79. Wittkop L et al (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11(5):363–371CrossRefPubMedGoogle Scholar
  80. World Health Organization (2012) The HIV drug resistance report – 2012. World Health Organization, GenevaGoogle Scholar
  81. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection – recommendations for a public health approach. World Health Organization, GenevaGoogle Scholar
  82. World Health Organization, UNAIDS, UNICEF (2011) Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. World Health Organization, GenevaGoogle Scholar
  83. Yerly S et al (1999) Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354(9180):729–733CrossRefPubMedGoogle Scholar
  84. Yerly S et al (2004) Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 9(3):375–384PubMedGoogle Scholar
  85. Yerly S et al (2009) The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 23(11):1415–1423CrossRefPubMedGoogle Scholar
  86. Young B et al (2011) Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 16(2):253–256CrossRefPubMedGoogle Scholar
  87. Yu D et al (2011) HIV drug resistance assessment in the Western Pacific region. A systematic review. AIDS Rev 13(4):214–226PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Laura Marije Hofstra
    • 1
    • 2
  • Jean-Claude Schmit
    • 1
  • Annemarie M. J. Wensing
    • 2
  1. 1.Department of Infection and ImmunityLuxembourg Institute of HealthLuxembourgLuxembourg
  2. 2.Department of Medical MicrobiologyUniversity Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations